Claims for Patent: 6,555,377

Summary for Patent: 6,555,377

Title:	Process for production of mammalian cell lines
Abstract:	Described is a process for generating a mammalian cell line from primary mammalian cells, comprising the step of: a) pre-treating a culture of said primary mammalian cells or a suspension thereof with at least one glucocorticoid, b) optional step comprising obtaining a suspension of said pre-treated culture of step a), c) transferring into the pre-treated cells of the suspension of step a) or b) at least one nucleic acid vector which is not of retroviral origin and which is competent to immortalize said pre-treated cells and d) culturing the transferred cells of step c). Furthermore, mammalian cell lines and cells obtainable by the described process are provided as well as pharmaceutical and diagnostic compositions containing such cells.
Inventor(s):	Braun; Serge (Dorlisheim, FR), Perraud; Frederic (Geudertheim, FR)
Assignee:	Transgene S.A. (Strasbourg, FR)
Application Number:	09/559,782
Patent Claims:	1. A process for generating a mammalian cell line from primary mammalian cells, comprising: a) pre-treating a culture of primary mammalian cells or a suspension thereof with at least one glucocorticoid, b) if said culture of primary mammalian cells is not in the form of a suspension, obtaining a suspension of the pre-treated culture of step a), c) transferring into the pre-treated cells of the suspension at least one nucleic acid vector which is not of retroviral origin and which is competent to immortalize said pre-treated cells, and d) culturing the transferred cells of step c). 2. A process for generating a mammalian cell line from primary mammalian cells, comprising: a) obtaining a culture of said primary mammalian cells, b) pre-treating the culture of step a) with at least one glucocorticoid, c) obtaining a suspension of said pre-treated culture of step b), d) transferring into the pre-treated cells of the suspension of step c) at least one nucleic acid vector which is not of retroviral origin and which is competent to immortalize said pre-treated cells and e) culturing the transferred cells of step d). 3. A process for generating a mammalian cell line from primary human muscle cells, comprising: a) obtaining a culture of said primary human muscle cells, b) obtaining a suspension of said cultured primary human muscle cells of step a), c) pre-treating the suspension of step b) with at least one glucocorticoid, d) transferring into the pre-treated cells of the suspension of step c) at least one nucleic acid vector which is not of retroviral origin and which is competent to immortalize said pre-treated cells and e) culturing the transferred cells of step d). 4. The process of claim 1, wherein said suspension is obtained by a treatment of said cultured primary mammalian cells or of said pre-treated culture with at least one compound capable of disaggregating cell organization. 5. The process of claim 4 wherein said compound is an enzyme selected from the group consisting of pancreatin, collagenase, dispase, trypsin, hyaluronidase, and equivalents of any one thereof. 6. The process of claim 1, wherein said glucocorticoid is dexamethasone, betamethasone, budesonide, hydrocortisone, prednisone, prednisolone, triamcinolone or flunisolide. 7. The process of claim 1, wherein said glucocorticoid is in a lipid soluble form, an ethanol soluble form or a water soluble form. 8. The process of claim 1, wherein said glucocorticoid is a synthetic glucocorticoid. 9. The process of claim 1, wherein said pre-treatment comprises contacting said culture of primary mammalian cells or a suspension thereof with said glucocorticoid. 10. The process of claim 9 wherein said pre-treatment is applied at least 3 hours before the transferring step. 11. The process of claim 9 wherein the glucocorticoid concentration in the pretreatment step ranges from 10.sup.-4 M to 10.sup.-10 M. 12. The process of claim 1, wherein said nucleic acid vector competent to immortalize cells comprises at least one nucleic acid sequence encoding an oncogenic polypeptide selected from the group consisting of myc, SV40 T antigen, SV40 t antigen, papillomaviruses E6 and E7, polyoma Large T gene, EBV, ras, adenovirus E1, p53 and oncogenic parts of any one thereof. 13. The process of claim 12 wherein said nucleic acid vector further comprises elements necessary for the expression of said nucleic acid sequence. 14. The process of claim 13, wherein said elements necessary for the expression of said nucleic acid sequence are activable by glucocorticoids. 15. The process of claim 13, wherein said nucleic acid vector is a plasmid. 16. The process of claim 13, wherein said nucleic acid vector further comprises a second nucleic acid sequence encoding all or part of a therapeutic or prophylactic polypeptide. 17. The process of claim 1, wherein the nucleic acid sequence competent to immortalize cells is transferred into pre-treated cells of said suspension by a method selected from the group consisting of viral infection, cationic lipid or cationic polymer transfection, calcium phosphate transfection, electroporation, and combinations of any one thereof. 18. The process of claim 1, wherein said transferring step is performed in presence of at least one glucocorticoid. 19. The process of claim 1, wherein the nucleic acid concentration in the transferring step ranges from 0.1 to 100 .mu.g/10.sup.6 cells. 20. The process of claim 1, wherein said primary mammalian cells are lymphocytes, fibroblasts, vein endothelium cells, retinal cells, endothelial cells, Schwann cells or osteoblasts. 21. The process of claim 1, wherein said glucocorticoid is a non-synthetic glucocorticoid.

Details for Patent 6,555,377

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	05/05/2004		2019-04-27
Bausch & Lomb Incorporated	VITRASE	hyaluronidase	Injection	021640	12/02/2004		2019-04-27
Amphastar Pharmaceuticals, Inc.	AMPHADASE	hyaluronidase	Injection	021665	10/26/2004		2019-04-27